Vanessa Malier

Vanessa Malier is Strategic Advisor.

A biologist by training, Vanessa began her career at CDC Innovation as an analyst and then joined a start-up based in California to be responsible for business development. In 2003, Vanessa joined Ipsen as Strategic Advisor to the CEO, then was appointed Product Leader for febuxostat, which obtained registration with the EMA in 2008. Vanessa was then successively appointed Senior Director, Business Development Oncology in 2009 then VP, R&D Strategic Planning in 2011.

Vanessa graduated from the Ecole Normale Supérieure de Cachan and in Immunology from the Institut de Pasteur. Vanessa joined Kurma in September 2013 and is in charge of the investment in Xeltis (Switzerland).